PT - JOURNAL ARTICLE AU - Emmenegger, Marc AU - Fiedler, Sebastian AU - Brugger, Silvio D. AU - Devenish, Sean R. A. AU - Morgunov, Alexey S. AU - Ilsley, Alison AU - Ricci, Francesco AU - Malik, Anisa Y. AU - Scheier, Thomas AU - Batkitar, Leyla AU - Madrigal, Lidia AU - Rossi, Marco AU - Lynn, Andrew K. AU - Saleh, Lanja AU - von Eckardstein, Arnold AU - Knowles, Tuomas P. J. AU - Aguzzi, Adriano TI - Both COVID-19 infection and vaccination induce high-affinity cross-clade responses to SARS-CoV-2 variants AID - 10.1101/2022.04.07.22273545 DP - 2022 Jan 01 TA - medRxiv PG - 2022.04.07.22273545 4099 - http://medrxiv.org/content/early/2022/04/10/2022.04.07.22273545.short 4100 - http://medrxiv.org/content/early/2022/04/10/2022.04.07.22273545.full AB - The B.1.1.529 (omicron) variant has rapidly supplanted most other SARS-CoV-2 variants. Using microfluidics-based antibody affinity profiling (MAAP), we have recently shown that current therapeutic monoclonal antibodies exhibit a drastic loss of affinity against omicron. Here, we have characterized affinity and IgG concentration in the plasma of 39 individuals with multiple trajectories of SARS-CoV-2 infection and/or vaccination as well as in 2 subjects without vaccination or infection. Antibody affinity in patient plasma samples was similar against the wild-type, delta, and omicron variants (KA ranges: 122±155, 159±148, 211±307 μM-1, respectively), indicating a surprisingly broad and mature cross-clade immune response. We then determined the antibody iso- and subtypes against multiple SARS-CoV-2 spike domains and nucleoprotein. Postinfectious and vaccinated subjects showed different profiles, with IgG3 (p = 0.002) but not IgG1, IgG2 or IgG4 subtypes against the spike ectodomain being more prominent in the former group. Lastly, we found that the ELISA titers against the wildtype, delta, and omicron RBD variants correlated linearly with measured IgG concentrations (R=0.72) but not with affinity (R=0.29). These findings suggest that the wild-type and delta spike proteins induce a polyclonal immune response capable of binding the omicron spike with similar affinity. Changes in titers were primarily driven by antibody concentration, suggesting that B-cell expansion, rather than affinity maturation, dominated the response after infection or vaccination.Competing Interest StatementTPJK is a member of the board of directors of Fluidic Analytics. AA is a member of the clinical and scientific advisory board of Fluidic Analytics. AA is a member of the board of directors of Mabylon AG and AB2Bio AG. AKL, SF, SRAD, ASM, AYM, AI, and FR are employees of Fluidic Analytics. All other authors declare no competing interest.Funding StatementInstitutional core funding by the University of Zurich and the University Hospital of Zurich, Swiss National Science Foundation (SNF) grant #179040 as well as Driver Grant 2017DRI17 of the Swiss Personalized Health Network to AA; funding by grants of Innovation Fund of the University Hospital Zurich (INOV00096), and of the NOMIS Foundation, the Schwyzer Winiker Stiftung, and the Baugarten Stiftung (coordinated by the USZ Foundation, USZF27101) to AA and ME as well as the USZ Foundation USZF270808 to SDB.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All experiments and analyses involving samples from human donors were conducted with the approval of the ethics committee of the canton Zurich, Switzerland (KEK-ZH-Nr. 2015-0561, BASEC-Nr. 2018-01042, and BASEC-Nr. 2020-01731), in accordance with the provisions of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Conference on Harmonisation. All subjects enrolled in the study signed the hospital-wide General Consent of the University Hospital Zurich, Switzerland.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.